drugset / Trial / NCT04795713
Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1
Non-randomizedSequentialOpen-labelTreatment
Summary
This will be a Phase 1 Open-label, dose escalation and expansion study of MT-6402 (an Engineered Toxin Body (ETB)) in subjects with advanced solid cancer that expresses PD-L1
Timeline
- Start
- 2021-05-27
- Primary completion
- 2024-10-31
- Completion
- 2024-10-31
Outcome
Outcome not reported
Stopped: “Terminated by Sponsor”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MT-6402 | Other / unclassified | — | Intravenous |